Business Wire

NOW-HEALTH-INTERNATIONAL

7.6.2021 10:02:06 CEST | Business Wire | Press release

Share
Now Health International Teams up With Starr Insurance Companies

Now Health International Group, a leading International Private Medical Insurance (IPMI) provider, has announced a new program with Starr Insurance Companies, a leading global insurance company, to drive forward ambitious growth plans in Europe.

This mutually beneficial relationship combines Now Health International’s global presence and expertise in providing high quality international health insurance solutions and state of the art digital tools, including the recently launched Mobile Pass innovation, with Starr’s long-standing global knowledge and ability to deliver customised solutions across Europe through a specialised team of professionals dedicated to offering the best service to its customers.

Under the new agreement, as of 1st March 2021, Starr Insurance Companies will insure all new and renewing business across Europe. Now Health International will continue to administer the international health insurance plans, including claims handling and customer service support. All members will also continue to benefit from access to Now Health International’s award-winning digital tools.

Zahir Sharif, Managing Director, Now Health International said, “At Now Health International we are committed to further building our presence in Europe and have ambitions to expand into new markets across the region. Starr Insurance Companies, with over 100-years of heritage, expertise and existing presence across global markets, is a well-placed partner to help us achieve this goal.”

Now Health International will continue to offer its existing products to members across Europe under the new partnership, including its flagship, benefit-rich WorldCare product, and its more affordable SimpleCare product for those looking for essential health cover. There will be no changes to plan benefits, pricing, or the customer service experience as a result of this arrangement.

The new program replaces Now Health International’s previous relationship with AXA PPP Healthcare. To ensure a smooth transition process for existing members, a runoff period will be deployed until 31st December 2021, seamlessly transitioning members to the new arrangement with Starr Insurance Companies at their next plan renewal.

Michel Faucher, Chief Commercial Officer, Now Health International added, “We are very excited about our new relationship and the opportunities it presents for us in the long term. I also want to reassure our members and partners that there will be complete continuity under the new arrangements, with the same market-leading plans and benefits, high standards of service, and state of the art digital tools our European customer base have come to expect.”

Santiago Mora, Head of International Accident & Health for Starr, said, “We’re excited to be the insurance provider for Now Health International, one of the fastest growing providers of medical insurance solutions for global expatriates.”

-ENDS-

Notes to Editors: About Now Health International Group

The Now Health International Group consists of Now Health International and Best Doctors Insurance. Now Health International is one of the fastest growing providers of International Private Medical Insurance (IPMI) solutions for Global Expatriates, High-Net-Worth individuals and Companies. Now Health has offices in the UK, Malta, UAE, China, Hong Kong, Singapore and Indonesia. Best Doctors Insurance is a Bermuda/ Miami based major medical insurance provider with offices in the US, Canada and Ecuador and distribution throughout Central and Latin America, the Caribbean and Canada.

The combined business is a global top tier specialist IPMI provider, with complementary products, distribution and geographies. The operation spans four continents, with 11 sales &/or service offices, 125,000+ members, 370+ employees and 5,000+ distribution partners.

www.now-health.com

www.bestdoctorsinsurance.com

Notes to Editors: About Starr Insurance Companies

Starr Insurance Companies (or Starr) is a marketing name for the operating insurance and travel assistance companies and subsidiaries of Starr International Company, Inc. and for the investment business of C. V. Starr & Co., Inc. and its subsidiaries. Starr is a leading insurance and investment organization with a presence on six continents; through its operating insurance companies, Starr provides property, casualty, and accident and health insurance products as well as a range of specialty coverages including aviation, marine, energy and excess casualty insurance. Starr’s insurance company subsidiaries domiciled in the U.S., Bermuda, China, Hong Kong, Singapore, U.K. and Malta each have an A.M. Best rating of “A” (Excellent). Starr’s Lloyd’s syndicate has a Standard & Poor’s rating of “A+” (Strong).

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release

The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req

SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release

Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5

EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release

EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release

The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye